Physician profile
Maxine Lubkin
NPI 1841215795
$7,340.42
in general payments reported to CMS, 2019-2025
30 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $863 · 2022: $1,481 · 2023: $1,626 · 2024: $2,052 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,965 · Education: $31.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,964.82 |
| Education | $31.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,704.06 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,635.34 | 2021-2025 | |
| Janssen Biotech, INC. | $752.72 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $712.22 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $302.80 | 2022-2025 | Ibsrela |
| Pfizer INC. | $299.41 | 2021-2025 | |
| Sandoz INC. | $240.27 | 2023-2025 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $234.69 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $199.74 | 2022-2024 | Rebyota |
| Celgene Corporation | $170.16 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $145.00 | 2021-2024 | Linzess |
| Lilly USA, LLC | $138.89 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $112.30 | 2022-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $93.61 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $82.55 | 2022-2024 | Ocaliva |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $81.54 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.72 | 2023-2024 | Cyltezo |
| Celltrion USA INC. | $61.10 | 2024-2025 | Zymfentra, Vegzelma |
| Daiichi Sankyo INC. | $51.67 | 2022-2023 | Injectafer |
| Organon LLC | $47.48 | 2024-2025 | Hadlima |
| Nestle Healthcare Nutrition INC. | $35.49 | 2022 | |
| Braintree Laboratories, INC. | $29.42 | 2022-2024 | Suflave, Sutab |
| Amgen INC. | $24.09 | 2023 | Avsola, Amjevita |
| Vivus LLC | $22.18 | 2022 | |
| Madrigal Pharmaceuticals | $21.14 | 2024 | Resmetirom |
| Teva Pharmaceuticals USA, INC. | $18.23 | 2024 | Simlandi |
| Genzyme Corporation | $17.78 | 2024 | |
| Aimmune Therapeutics, INC. | $16.66 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.68 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxine Lubkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.